While Russia could have change into the primary nation on the planet to grant regulatory approvals toits COVID-19 vaccine, the accelerated fee at which the vaccine has been developed has been elevating eyebrows. Dr Randeep Guleria, the director of All India Institute for Medical Sciences echoed related sentiments. He underlined that it’s essential to verify the security and efficacy of the Russian vaccine candidate. He additionally stated that India has the capability for mass manufacturing of the vaccine.
In an interview with Hindustan Times, Dr Guleria stated, “If Russia’s vaccine is profitable, then we should see critically whether or not it’s secure and efficient. There shouldn’t be any negative effects of the vaccine and it ought to present good immunity and safety. India has the capability for mass manufacturing of the vaccine.